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The stroma of breast cancer can promote the disease’s progression, but whether its composition and functions
are shared among different subtypes is poorly explored. We compared stromal components of a luminal [mouse
mammary tumor virus (MMTV)–Neu] and a triple-negative/basal-like [C3(1)–Simian virus 40 large T antigen (Tag)]
genetically engineered breast cancer mouse model. The types of cytokines and their expression levels were very
different in the two models, as was the extent of innate immune cell infiltration; however, both models showed
infiltration of innate immune cells that expressed matrix metalloproteinase 9 (MMP9), an extracellular protease
linked to the progression of many types of cancer. By intercrossing with Mmp9 null mice, we found that the
absence of MMP9 delayed tumor onset in the C3(1)-Tag model but had no effect on tumor onset in the MMTV-Neu
model. We discovered that protein levels of insulin-like growth factor binding protein-1 (IGFBP-1), an MMP9
substrate, were increased in C3(1)-Tag;Mmp9−/− compared to C3(1)-Tag;Mmp9+/+ tumors. In contrast, IGFBP-1
protein expression was low in MMTV-Neu tumors regardless of Mmp9 status. IGFBP-1 binds and antagonizes
IGFs, preventing them from activating their receptors to promote cell proliferation and survival. Tumors from C3(1)-
Tag;Mmp9−/− mice had reduced IGF-1 receptor phosphorylation, consistent with slower tumor onset. Finally,
gene expression analysis of human breast tumors showed that high expression of IGFBP mRNA was strongly
correlated with good prognosis but not when MMP9 mRNA was also highly expressed. In conclusion, MMP9 has
different effects on breast cancer progression depending on whether IGFBPs are expressed.
Neoplasia (2015) 17, 421–433Introduction
Breast cancer is classified on the basis of gene expression: About 20%
of human breast cancers overexpress human epidermal growth factor
receptor 2 (HER2/ErbB2) and these cancers have a worse prognosisthan the more common estrogen and progesterone (hormone)
receptor–positive subtypes [1]. Cases negative for hormone receptors
and ErbB2 (triple negative subtypes) have the worst prognosis and
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into luminal and basal-like subtypes, based on global gene expression
profiles [3]. Luminal breast cancers are often estrogen receptor– and/
or HER2/ErbB2-positive, while the majority of basal-like breast
cancers are triple negative [4].
In themousemammary tumor virus long terminal repeat driven-Neu
(MMTV-Neu) model [5], the rodent homologue of HER2/ErbB2 is
overexpressed. The MMTV-Neu model is a model of human luminal
breast cancer as defined by expression profiling [6]. In another breast
cancer model, expression of the Simian virus (SV) 40 large T antigen
(C3(1)-Tag) [7] in the mammary epithelium induces estrogen
receptor–, progesterone receptor–, and HER2-negative tumors [8],
with expression profiles resembling human basal-like breast cancers [6].
In the MMTV-Neu model, the activation of the Ras/phosphoinositide
3-kinase pathway drives tumor progression, while in the C3(1)-Tag
model, it is the inactivation of p53 and Rb that is the driving force.
Breast tumors contain stromal cells, such as immune, mesenchy-
mal, and vascular cells, which communicate with cancer cells.
Genetically engineered mouse models of cancer enable studies of how
driving oncogenic changes influence tumor progression in the context
of a stromal response [9–11]. The communication between cancer
and stromal cells is mediated by, e.g., growth factors, cytokines,
proteases, and extracellular matrix proteins [12–14]. These extracel-
lular factors, together with the stromal cells, constitute the tumor
microenvironment. Experimental studies have shown that the
components of the tumor microenvironment possess functions that
are vital for tumor growth, including support of angiogenesis
(reviewed in [12]). However, it is still unclear whether specific
stromal components have the same effects on tumor progression in
different subtypes of cancer arising in the same organ.
Many approaches have been undertaken to block the influence of
the microenvironment on cancer progression, including the pharma-
cological inhibition of matrix metalloproteinases (MMPs) [15–17].
MMPs belong to a large family of proteases involved in the
degradation and modulation of extracellular proteins. The enzymatic
activities of MMPs are important in the tumor microenvironment
because proteolysis can regulate a range of different processes, such as
angiogenesis and growth factor bioavailability [18].
Despite strong experimental proof that MMPs promote tumor
initiation and progression, clinical trials using MMP inhibitors have
failed (reviewed in [15,19]). In hindsight, the trials were not
optimally designed: For example, they enrolled patients with
late-stage cancer even though preclinical experiments showed that
MMPs should be blocked in early-stage cancer [20]. Furthermore, no
effort was made to ensure that MMPs were overexpressed in the
cancer of the treated patients [19]. The design of the clinical trials also
ignored the fact that MMPs can have different effects on tumor
progression depending on the substrates they act on [21].
MMP9, one of the most studied MMPs in cancer, is mainly
expressed by tumor-infiltrating myeloid cells [20,22–25]. Deletion of
Mmp9, the gene encoding for MMP9, delays tumor onset or slows
tumor progression in many genetically engineered mouse models of
cancer [20,22–25]. Interestingly, in these models, the p53 and Rb
tumor suppressors were inactivated, e.g., by interaction with the
SV40 large T antigen or human papilloma virus early region
oncogenes [20,22,23]. In contrast, the genetic deletion of Mmp9 in a
model of mammary carcinoma driven by expression of tyrosine
kinases [MMTV–polyoma middle T antigen (PyMT)] had no effect
on tumor onset or primary tumor growth [24]. It is unclear whetherthis difference in the effects of MMP9 on tumor progression between
the models was due to the different oncogenic events that drive the
cancers or because the tumors originated from different tissues.
In this study, we compared expression levels of different stromal
factors between the luminal MMTV-Neu and the basal-like
C3(1)-Tag murine breast cancer models. Interestingly, we found
that MMP9 was expressed by myeloid cells in both models, yet it only
influenced tumor onset in the basal-like C3(1)-Tag model. We
discovered that the protein levels of the MMP9 substrate insulin-like
growth factor binding protein-1 (IGFBP-1) were increased in the
absence of MMP9 only in the C3(1)-Tag model, the model that
depended on MMP9 for tumor progression. Furthermore, in data
sets of human breast cancer samples, high mRNA expression of
IGFBPs correlated with a good prognosis, except when these
tumors also expressed high levels of MMP9 mRNA. Collectively,
our findings show that MMP9 and IGFBPs have different
subtype-dependent effects on breast cancer and that a nuanced
understanding of tumor biology is necessary to successfully target
these stromal factors.
Materials and Methods
Mice
MMTV-Neu [5], C3(1)-Tag [7], and Mmp9−/− [26] mice have all
been described previously. All three mice strains were used on the FVB/
n background. MMTV-Neu and C3(1)-Tag mice were each crossed
with Mmp9−/− mice, and the offspring were further intercrossed to
generate MMTV-Neu;Mmp9 +/+ , MMTV-Neu;Mmp9 +/− ,
MMTV-Neu;Mmp9−/−, C3(1)-Tag;Mmp9+/+, C3(1)-Tag;Mmp9+/−,
and C3(1)-Tag;Mmp9−/− mice. Only mice hemizygous for the
MMTV-Neu or C3(1)-Tag transgenes were used to compare tumor
onset. All animal experiments were conducted in accordance with
procedures approved by the Institutional Animal Care and Use
Committee at the University of California, San Francisco.
Tumor Growth
Tumor growth was monitored in all 10 mammary glands by
weekly palpations in MMTV-Neu;Mmp9 +/+ (n = 47),
MMTV-Neu;Mmp9+/− (n = 48), MMTV-Neu;Mmp9−/− (n = 39),
C(3)1-Tag;Mmp-9+/+ (n = 18), C(3)1-Tag;Mmp9+/− (n = 25), and
C(3)1-Tag;Mmp9−/− (n = 13) mice. The length and width of all
palpable tumors were measured by caliper, and the volume was
calculated using the formula: volume = width2 × length/2.
Histology and Immunostaining
Dissected mammary carcinomas and lungs were fixed in 4%
paraformaldehyde, processed in alcohol, embedded in paraffin, and
cut into 5-μm-thick sections. Sections were stained with hematoxylin
and eosin, Mayer's hematoxylin with Masson's trichrome, or
Picrosirius Red using standard protocols. Lung metastatic burden
was examined in tissue sections from lungs of C3(1)-Tag;Mmp9+/+
(n = 21), C3(1)-Tag;Mmp9+/− (n = 19), and C3(1)-Tag;Mmp9−/−
(n = 14) mice, which were sacrificed at Institutional Animal Care and
Use Committee–approved end stage (i.e., when the largest tumor
reached 2 cm in diameter or a tumor had ulcerated). The percentage
of the lung area occupied by metastasis, the number of metastatic foci,
and the average size of each metastatic lesion were quantified on cross
sections of lungs stained with hematoxylin and eosin using
ImageScope software (Aperio Technologies, Vista, CA). Fibrillar
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under cross-polarized light.
For immunostainings, antigen retrieval was performed by incubation
with proteinase K (S3020; DAKO, Glostrup, Denmark) for 5 minutes at
37°C. Before adding primary antibodies, sections were blocked with a
mixture of goat serum and 2.5% BSA (blocking buffer). Antibodies
against Ly6B.2 (clone 7/4, rat anti-mouse mAb, #CL8993 AP-1,
Cedarlane Laboratories, Burlington, NC) and F4/80 (rat anti-mouse
mAb, MCA497R; Serotec, Raleigh, NC) were used at 1:400 dilutions in
blocking buffer. Biotinylated anti-rat IgG Fab fragment (sc-3826; Santa
Cruz Biotechnology, Dallas, TX) was diluted 1:400 in blocking buffer
followed by incubation with VECTASTAINABC-Elite solution (Vector
Labs, Burlingame, CA). To detect IGFBP-1 and phospho–IGF-1
receptor (IGF-1R), the tumor sections were heat-treated in Tris-EDTA
(10 mM Tris, 1 mM EDTA, pH 9.0) buffer for 6 minutes before
blocking and incubation with anti–IGFBP-1 (1:200 dilution, sc-13097;
Santa Cruz Biotechnology) or anti-phospho (Y1161) IGF-1R (1:100
dilution, ab39398; Abcam, Cambridge, MA). Antibody binding was
detected with biotin-conjugated anti-rabbit antibodies (1:250 dilution,
sc-3840; Santa Cruz Biotechnology) and VECTASTAIN ABC-Elite
solution and visualized by 3,3′-diaminobenzidine chromogen (Vector
Labs). To quantify IGFBP-1 and phopho–IGF-1R proteins in tumor
sections, we first stained for these antigens and then scanned tissue
sections from C3(1)-Tag;Mmp9+/+ (n = 10) and C3(1)-Tag;Mmp9−/−
(n = 10) tumors. We then used ImageScope software with the Color
Deconvolution Algorithm to quantify the signal intensity of 3,3′-di-
aminobenzidine staining (using the H-score: the sum of three times the
area with strong staining intensity and two times area with medium
staining intensity) to compare signal intensity.
The number of cells positive for Ly6B.2 (neutrophils/monocytes)
and F4/80 (macrophages) was quantified in tumors from
MMTV-Neu;Mmp9+/+ (n = 3), MMTV-Neu;Mmp9−/− (n = 4),
C(3)-1-Tag;Mmp9+/+ (n = 5), and C(3)-1-Tag;Mmp9−/− (n = 4)
mice. Four representative images were acquired from the central parts
of each tumor, and the number of positive cells was counted using
NIH ImageJ software. For immunofluorescence staining of MMP9,
a rabbit anti-mouse polyclonal MMP9 antibody [27] was used at
1 μg/ml together with the Ly6B.2 and F4/80 antibodies. Sections
were incubated with the primary antibodies for 2 hours at room
temperature before detection with Alexa Fluor 568–conjugated goat
anti-rat IgG (Invitrogen, Carlsbad, CA) or Alexa Fluor 647–conjugated
goat anti-rabbit IgG (Invitrogen). Secondary antibodies were diluted
1:150 in blocking buffer and incubated for 30 minutes at room
temperature, followed by the addition of 4′,6-diamidino-2-phenylindole
for labeling of cell nuclei. Sections were mounted with Fluorogel
(Electron Microscopy Sciences, Hatfield, PA) and sealed with Cytoseal
(Thermo Fisher Scientific Inc, Waltham, MA). The percentage of cells
double positive forMMP9 and either Ly6B.2 (neutrophils/monocytes) or
F4/80 (macrophages) was quantified in tumors fromMMTV-Neu (n = 5
for neutrophils and n = 4 for macrophages) and C(3)-1-Tag mice (n = 5
for both neutrophils and macrophages) at the tumor-stroma interphase
(where most inflammatory cells were found) using NIH ImageJ software.
Examination of Angiogenesis
Tumor vascularity and pericyte coverage of the vasculature were
determined as previously described [28]. Briefly, tumor sections of
MMTV-Neu;Mmp9+/+ (n = 8), C3(1)-Tag;Mmp9+/+ (n = 8), and
C3(1)-Tag;Mmp9−/− (n = 8) mice were double immunofluorescence
stainedwith anti-CD31 (1:25 dilution, ab28364; Abcam) andα smoothmuscle actin (αSMA; 1:1500 dilution, A5228; Sigma-Aldrich, St Louis,
MO). CD31-positive (endothelial cell marker) and αSMA-positive
(pericyte marker) areas were defined as those with a fluorescence
intensity above 150% of the mean of background intensity levels, as
determined by Volocity software (PerkinElmer, Waltham, MA).
Pericyte coverage was calculated by dividing the αSMA-positive
(pericyte) area by the CD31-positive (endothelial cell) area. All images
were analyzed without knowledge of mouse genotype.
Protein Arrays
Tumors were harvested, snap frozen, and stored in liquid nitrogen until
use. The frozen tumor samples were homogenized on ice and transferred to
lysis buffer (1%NP-40, 20 mMTris-HCl, 137 mMNaCl, 10% glycerol,
2 mM EDTA, pH 8.0, containing EDTA-free proteinase inhibitor
cocktail) for 30minutes at 4°C on a rocking table. Lysates were centrifuged
twice at 13,000g for 10 minutes at 4°C. Samples were analyzed using a
Mouse Cytokine Antibody Array, Panel A and a Mouse Angiogenesis
Antibody Array (R&D Systems, Minneapolis, MN) according to the
manufacturer’s instructions. Relative protein levels were determined by the
intensity of spots representing a single protein on radiographic films. The
intensity of spots was analyzed by Adobe Photoshop (version CS6) and
normalized to internal standards on the arrays. Normalized data for
individual tumors were plotted in a heat map and ranked according to the
detected levels, with the highest at the top. For proteins analyzed by both
the Cytokine and Angiogenesis arrays, highly reproducible expression levels
were obtained when lysates from the same tumor were tested on the two
different arrays. These proteins are therefore only represented in the figures
for the cytokine/chemokine arrays. Statistical significance was determined
using multiple t tests with the Holm-Šídák correction for multiple
comparisons, with α = 0.05, using GraphPad Prism software (version 6;
GraphPad Software, La Jolla, CA).
Necrosis Quantification
Micrographs of Masson’s trichrome–stained C3(1)-Tag tumor
sections were captured using a Panoramic MIDI slide scanner
(3DHISTECH Ltd, Budapest, Hungary), which provided overview
pictures of the entire tissue section. Using 3DHISTECH software,
necrosis was defined as areas with pale staining, containing dead cells
and infiltrating leukocytes. The necrotic areas as percentage of the
total tumor area were calculated for each tissue section.Survival Analysis for Human Breast Cancer Patients
Four expression profile data sets from whole tumor tissue (including both
cancer and stromal cells) of human breast cancer with clinical information
were used: GSE1456 (overall survival, n = 159) [29], GSE2034
(metastasis-free survival, n = 286) [30], GSE2990 (relapse-free survival, n =
187) [31], and GSE3494 (overall survival, n = 236) [32]. Survival analysis
based on expression levels of MMP9 and IGFBPs was conducted as
previously described [33]. Briefly, signal intensities of each probe were
acquired from the Gene Expression Omnibus database and analyzed by
ExpressionConsole software (Affymetrix, Santa Clara, CA). The cut-off level
for dividing patients into the high or low expression groups was determined
by the X-Tile software [34] and was followed by Kaplan-Meier survival
analysis using GraphPad Prism (version 5; GraphPad Software).
Statistical Analysis of Data from Mouse Tumors
GraphPad Prism version 5 (GraphPad Software) was used to
evaluate myeloid cell infiltration data, chemokine levels, and
tumor-free survival. For all analyses, α = 0.05.
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Figure 1. The tumor stroma of the MMTV-Neu and C3(1)-Tag mouse models of breast cancer is different. (A) Representative images of
mammary tumors at different stages from MMTV-Neu and C3(1)-Tag mice. Tumors were stained with hematoxylin and Masson’s
trichrome for visualization of collagen (which stains blue). Black arrows indicate deposition of collagen in the tumor microenvironment.
Scale bars, 100 μm. (B) Myeloid cell infiltration in carcinomas fromMMTV-Neu and C3(1)-Tag mice. The tumors were stained for reactivity
against antigen Ly6B.2 (clone 7/4, expressed on neutrophils/monocytes) and F4/80 (expressed on macrophages). Red arrows indicate
positively stained cells. Scale bars, 100 μm. (C) Significantly more neutrophils and macrophages were detected in tumors from C3(1)-Tag
(n = 5) than MMTV-Neu (n = 3 for macrophage analysis and n = 5 for neutrophil analysis) mice (P = .008 and P = .04, respectively,
Mann-Whitney, two-sided). (D) Relative protein levels of a panel of chemokines/cytokines measured on whole-tumor lysates from
MMTV-Neu (n= 4) and C3(1)-Tag (n= 4) tumors. Each column represents a tumor from an individual mouse. The measured protein levels
were normalized to an internal assay standard and plotted in a heat map. Statistical significance was determined by t tests using the Holm-
Šídák method to correct for multiple comparisons, and the asterisk indicates P b .05.
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Increased Infiltration of Myeloid-Derived Innate Immune
Cells in C3(1)-Tag Compared to MMTV-Neu Tumors
We first compared the histology of mammary tumors in
MMTV-Neu and C3(1)-Tag mice. There was a pronounced increasein stromal components, including collagen deposition, in C3(1)-Tag
lesions versus MMTV-Neu lesions. This difference was already
observable at the pre-invasive mammary intraepithelial neoplasia stage
and became even more striking as the tumor progressed from low- to
high-grade carcinomas (Figures 1A and S1). Collagen fibers were
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Figure 2. Similar angiogenic microenvironments in the MMTV-Neu
and C3(1)-Tagmousemodels of breast cancer. (A) The vascularity, as
determined by the tumor area staining for the endothelial marker
CD31,was similar inMMTV-Neu (n=8) andC3(1)-Tag tumors (n=8).
(B) Relative protein levels of a panel of angiogenic factors measured
onwhole-tumor lysates fromMMTV-Neu (n=3) andC3(1)-Tag (n=3)
tumors. Each column represents a tumor from an individual mouse.
The measured protein levels were normalized to an internal assay
standard and plotted in a heat map. Statistical significance was
determined by t tests using the Holm- Šídák method to correct for
multiple comparisons, and the asterisk indicates P b .05.
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they were almost exclusively found at the tumor-stroma border in
MMTV-Neu tumors (Figure S1).
We next compared the infiltration of two broad classes of myeloid
cells, neutrophils/monocytes and macrophages, in the two cancer
models by immunohistochemistry (Figure 1B). C3(1)-Tag tumors
had 25-fold higher numbers of cells expressing the neutrophil/
monocyte marker 7/4 (P = .008, two-sided Mann-Whitney) and a
three-fold higher infiltration of cells expressing the macrophagemarker F4/80 (P = .04, two-sided Mann-Whitney) than
MMTV-Neu tumors (Figure 1C ). The pronounced difference in
the infiltration of innate immune cells between the two breast cancer
models suggested different cytokine milieus. We therefore surveyed
the relative protein levels of a panel of cytokines in whole-tumor
lysates using an antibody-based protein array (Figure 1D). About half
of the assayed cytokines, including CCL2, CCL5, CXCL2, CXCL9,
and CXCL10, were present at significantly higher levels in the
C3(1)-Tag tumors than in the MMTV-Neu tumors (P b .05, t tests and
using the Holm-Šídák method to correct for multiple comparisons).
These CC and CXC chemokine family members are chemotactic for,
e.g., neutrophils, monocytes, and macrophages [35,36].MMP9 Influences Tumor Onset of C3(1)-Tag, but Not
MMTV-Neu, Mouse Mammary Carcinomas
Tumor-infiltrating myeloid cells are important contributors of
tumor angiogenesis [37]. Therefore, the significantly higher levels
of myeloid cells in the C3(1)-Tag tumors suggested that vascularity
would be different between the two models. Yet, the number of
tumor vessels was similar in the MMTV-Neu and C3(1)-Tag
tumors (Figure 2A). The protein levels of a panel of angiogenic
factors were also similar between the two models, except
pentraxin-3, endothelin-1, and amphiregulin, which were all
increased in the C3(1)-Tag compared to the MMTV-Neu tumors
(Figure 2B; P b .05 after using the Holm-Šídák method to correct
for multiple comparisons).
MMP9 promotes tumor progression in several mouse models of
cancer [20,22,23,25]. Therefore, we next compared the effect of
MMP9 on tumor progression between our two models of different
breast cancer subtypes, focusing on high-grade carcinomas. We found
that in both subtype models, cells infiltrating the central, necrotic
areas of the tumors and cells located in the stroma at the periphery of
the tumors expressed MMP9. These MMP9-expressing cells
co-expressed either the neutrophil/monocyte marker or the macro-
phage marker (Figure 3, A and B). The percentages of macrophages
and neutrophils that expressed MMP9 were similar between the
models (53-60% of neutrophils and 7% of macrophages; Figure 3, C
and D). However, consistent with the very limited infiltration of
neutrophils in the MMTV-Neu model (Figure 1C), most of the
MMP9-expressing cells were macrophages in the MMTV-Neu
model, while most of the MMP9-expressing cells were neutrophils
in the C3(1)-Tag model (Figure 3, E and F ).
To investigate the effect of MMP9 on tumor progression in our
models, we crossed Mmp9−/− mice with MMTV-Neu and
C3(1)-Tag mice. We found that the absence of Mmp9 significantly
delayed tumor onset in the C3(1)-Tag model but had no effect on
tumor onset in the MMTV-Neu model (Figure 3, G and H ).
MMP9 has been shown to promote lung metastasis in the
MMTV-PyMT mouse model of breast cancer [24], but we did not
find any difference in overall lung metastatic burden, in the number
of metastatic foci, nor in the average size of the metastatic foci
between tumors of Mmp9+/+, Mmp9+/−, and Mmp9−/− mice of the
C3(1)-Tag strain (Figure S2).Absence of MMP9 Increases IGFBP-1 Protein and Suppresses
the IGF Signaling Pathway
The simplest explanation for the difference in effect of MMP9 on
tumor onset between the two breast cancer models might be the
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Figure 3.MMP9 promotes tumor onset in the C3(1)-Tag but not in the MMTV-Neu mouse model of breast cancer. (A) MMP9 is expressed
in neutrophils/monocytes and (B) macrophages in tumors of both MMTV-Neu and C3(1)-Tag mice. Tumors were stained for reactivity
against Ly6B.2 (clone 7/4, for neutrophils/monocytes), F4/80 (for macrophages), and MMP9. Lower panels are high magnifications of
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(C and D) The percentages of neutrophils/monocytes and macrophages expressing MMP9 were the same in the MMTV-Neu and
C3(1)-Tag models (n.s., not significant, Mann-Whitney, two-sided). (E and F) Neutrophils/monocytes constituted a higher percentage of
MMP9-expressing cells in the C3(1)-Tagmodels than in theMMTV-Neumodel (P= .09, Mann-Whitney), while macrophages constituted a
higher percentage of MMP9-expressing cells in the MMTV-Neu model than in the C3(1)-Tag model (P = .02, Mann-Whitney, two-sided).
(G) Kaplan-Meier curves showing tumor-free survival of MMTV-Neu;Mmp9+/+, MMTV-Neu;Mmp9+/−, and MMTV-Neu;Mmp9−/− mice.
No significant differences among the curves were observed. (H) Kaplan-Meier curves showing tumor-free survival of C3(1)-Tag;Mmp9+/+,
C3(1)-Tag;Mmp9+/−, and C3(1)-Tag;Mmp9−/− mice. A significant delay (P = .002, log rank test) in tumor onset was observed in
C3(1)-Tag;Mmp9−/− compared to C3(1)-Tag;Mmp9+/+ mice.
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MMTV-Neu tumors. However, since MMP9 acts through proteol-
ysis of its substrates, differences in expression levels of MMP9
substrates could be a contributing factor. MMPs can modulate
cytokine bioactivity by proteolysis [18]. We therefore investigatedwhether cytokine protein levels increased in the absence of MMP9,
when there was noMMP9-mediated proteolysis. No significant increases
in cytokine protein levels were found in C3(1)-Tag;Mmp9−/− tumors
compared to C3(1)-Tag;Mmp9+/+ tumors (Figure 4A), except for a
decrease in interleukin-1α (IL-1α). Comparison of the MMTV-
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significant changes (Figure 4B). Consistently, in the absence of MMP9,
there were no significant changes inmacrophage or neutrophil infiltration
(Figure 4C ).
MMP9 has complex effects on the tumor vasculature and can, for
example, both promote the formation of tumor vessels and decrease
vascular leakiness depending on tumor model and tumor stage ([20];
[25,28,38]). We previously reported that deletion of Mmp9 in
MMTV-Neu tumors had no effect on the number of vessels but
resulted in reduced coverage by pericytes [28]. Pericytes support
endothelial cells, thereby reducing vascular leakiness. In the
C3(1)-Tag model, deletion of Mmp9 instead led to a reduction inthe number of tumor vessels, but the vessels had the same amount of
vascular coverage by pericytes (Figure 5, A and B). Consistent with
reduced vascularity, an analysis of histologic sections of C3(1)-Tag
tumors revealed a non-significant trend toward increased necrosis in
the absence of MMP9 (Figure 5, C and D; P = .1, two-sided
Student’s t test, comparing size-matched tumors).
The reduced vascularity of the C3(1)-Tag;Mmp9−/− compared to
the C3(1)-Tag;Mmp9+/+ tumors led us to survey for differences in the
levels of angiogenic factors. IGFBP-1 is a known MMP9 substrate
[39,40]. Protein levels of IGFBP-1 were increased in the absence of
Mmp9 in the C3(1)-Tag tumors (Figure 6A; P = .02, t test; the
difference was not significant when corrected for multiple
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firmed that there was more IGFBP-1 protein in C3(1)-Tag;Mmp9−/−
tumors compared to C3(1)-Tag;Mmp9+/+ tumors (Figure 6, C andD).
In the MMTV tumors, IGFBP-1 protein levels were very low and not
influenced by Mmp9 status (Figure 6B; P = .73, t test, also not
significant using the Holm-Šídák method).
IGFBP-1 binds to IGF, preventing it from binding to and activating its
receptors. We used immunohistochemistry to examine the levels of the
phosphorylated (activated) IGF receptor (IGF-1R) and found decreased
IGF-1R activation in C3(1)-Tag;Mmp9−/− tumors compared to
C3(1)-Tag;Mmp9+/+ tumors (Figure 6, E and F ).High IGFBP Expression Is Associated with Good Prognosis in
Human Breast Cancer Patients Only When MMP9 Is
Expressed at Low Levels
High levels of IGFBP-1 can reduce cell proliferation and increase
cell death through sequestration of IGFs [41,42]. Our data from
mouse models suggested that IGFBPs are important substrates for
MMP9 in breast cancer and that interaction between the protease and
its substrate influences tumor progression. To investigate whether this
might have clinical relevance, we looked for correlations between
IGFBP and MMP9 mRNA expression and patient outcome in
publicly available gene expression data sets from human breast
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cancer. However, the related IGFBP-2, -3, -4, -5, -6, and -7 mRNA
were all expressed (Figure 7A), and of these, IGFBP-2, -3, -4, and -6proteins have been shown to be substrates of MMP9 [41,43–46]. We
found that high expression of IGFBP-2, -3, -4, -6, and -7 mRNA
was associated with good prognosis (Figure S3). On the contrary, high
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(Figure S4), consistent with prior reports [47,48]. High expression of
MMP9 mRNA was significantly correlated with the Elston grade of
breast cancer in the GSE3494 data set, which contained information
on tumor grade [Figure S4; P = .016, one-way analysis of variance
(ANOVA)]. Interestingly, in both the GSE3494 and GSE1456 data
sets, for patients that expressed high levels of MMP9 mRNA, high
expression of IGFBP-2, -3, -4, -6, or -7 mRNA was no longer
associated with good, but instead with poor, prognosis. In contrast,
low expression levels of these IGFBP mRNAs were associated with
poor outcome regardless ofMMP9 expression levels (Figures 7, B–D,F, and G, and S5). IGFBP-5 protein has not been shown to be an
MMP9 substrate. We found that high IGFBP-5 mRNA expression
was not associated with good, but instead with poor, prognosis.
Notably, high versus low MMP9 expression did not affect outcome
for patients with high IGFBP-5 expression levels (Figure 7E );
however, the number of patients with high IGFBP-5 levels was small
(n = 31) and it is therefore possible that a true association would be
missed. MMP2 is another protease that can digest IGFBPs [45], but
we found that high mRNA expression level of MMP2 was associated
with good prognosis in breast cancer (Figure S6A), also for patients
with high mRNA expression levels of IGFBP-2 or IGFBP-4
Neoplasia Vol. 17, No. 5, 2015 Matrix Metalloproteinase 9 in Breast Cancer Park et al. 431(Figure S6, B–D). Together, our data suggest that MMP9 cleaves
IGFBPs, which in turn leads to activation of pro-tumorigenic IGF
signaling pathways in breast cancer.
Discussion
Relatively little is known about how stromal responses differ between
different subtypes of breast cancer. Here, we compared the stromal
responses of the luminal MMTV-Neu and basal-like C3(1)-Tag
mouse models of breast cancer and found that C3(1)-Tag tumors had
higher levels of collagen, more inflammatory myeloid cells, and higher
levels of several chemokines (including CCL5, CXCL9, and
CXCL10) than the MMTV-Neu tumors. We further report that
the protease MMP9 only influenced tumor progression in the
C3(1)-Tag mouse model of breast cancer and that protein levels of a
known MMP9 substrate, IGFBP-1, correlated with the tumor-
promoting effect of MMP9 in the models. Finally, analysis of the
correlation between expression levels of MMP9 and IGFBPs versus
patient outcome suggested that these two genes interact to promote
human breast cancer.
Pro-angiogenic effects of MMP9 might be the cause for the delay
in tumor onset observed in the C3(1)-Tag;Mmp9−/−mice, and we did
indeed observe a reduced number of blood vessels in the
C3(1)-Tag;Mmp9−/− tumors compared to the C3(1)-Tag;Mmp9+/+
tumors. However, there was no significant difference in the level of
necrosis between tumors with and without Mmp9. Instead, we
detected increased levels of IGFBP-1, an MMP9 substrate [39], in the
C3(1)-Tag;Mmp9−/− compared to the C3(1)-Tag;Mmp9+/+ tumors.
Deletion of Mmp9 would be expected to result in decreased
proteolysis of IGFBP-1, consistent with this finding. The major
function of IGFBP-1 is to bind and sequester IGF-1, thereby
antagonizing IGFs’ ability to stimulate the proliferation of breast
cancer cells [41,49]. A slower cancer cell growth rate would increase
the time until tumors become detectable, consistent with our
observations of extended tumor-free survival in the C3(1)-Tag;Mmp9−/−
mice. On the basis of our preclinical data, we propose a model in which
high levels of IGFBPs are associated with good prognosis because they
sequester IGFs to reduce IGFR signaling and cancer proliferation.
However, in the presence of high levels of MMP9, the IGFBPs are
digested, IGFs are released, and cancer progression accelerates
(Figure 7H ). One way to test whether MMP9-mediated proteolysis of
IGFBP-1 is critical for tumor progression in the C3(1)-Tag model would
be to generate mice expressing IGFBP-1 with a mutatedMMP9 cleavage
site, so that it no longer can be processed by MMP9, and intercross such
mice with C3(1)-Tag.
It is interesting that in the C3(1)-Tag model, Mmp9 deletion
only resulted in increased IGFBP-1 levels, while IGFBP-2 and
IGFBP-3 levels were not altered. Mouse IGFBP-3 is an MMP9
substrate [44], but it can be cleaved by multiple other proteases.
It is therefore possible that other proteases compensate for the
depletion of MMP9 in the C3(1)-Tag mouse model. Our
analysis of the association of MMP9 and IGFBP levels with
prognosis in human data sets is intriguing, as it suggests a
population of breast cancer patients that could benefit from
treatment with MMP9 inhibitors. Further studies are needed to
confirm this possibility.
After crossing our models with Mmp9−/− mice, we found that
tumor onset was significantly delayed in the absence of MMP9 in the
C3(1)-Tag model, while there was no change in tumor onset in the
MMTV-Neu model. It is unclear why deletion of MMP9 had noeffect on tumor onset in the MMTV-Neu model, although it could
simply be that expression levels are somewhat lower to begin with or
that MMP9 is not activated to the same extent as in the C3(1)-Tag
tumors. However, the low level of IGFBP-1 in the MMTV-Neu
tumors (both with and without MMP9) may also be a contributing
factor. Lack of MMP9 also delays tumor onset in the pancreatic islet
cell carcinoma model (RIP1-Tag2) [20], a cancer model that, similar
to C3(1)-Tag, is driven by expression of the SV40 large T antigen
with p53 and Rb inactivation. In contrast, lack of MMP9 does not
affect tumor onset in the luminal MMTV-PyMT model, a model
that, like the MMTV-Neu model, is driven by activation of the Ras
pathway [24]. Together, these reports suggest that MMP9 has a
tumor-promoting effect in tumors driven by p53/Rb inactivation and
a minimal effect when Ras activation is driving the cancer.
We found a substantial difference in the levels of cytokines between
tumors of the MMTV-Neu and C3(1)-Tag models. Both types of
tumors originate from luminal mammary epithelial cells [5,7],
suggesting that the significant difference in stromal response between
the models is not due to the cell type of origin. Activated Ras can
transcriptionally induce chemokines involved in stromal cell recruit-
ment, including IL-8/CXCL8 [50], IL-6, and CXCL1 [51,52]. In
contrast, p53 can antagonize nuclear factor κB (NF-κB), thereby
suppressing the expression of its target genes [53]. Increased expression
of the NF-κB–regulated CXCL9 and CXCL10 chemokines has been
reported in the thymuses of p53-deficient mice compared to their
wild-type littermates [54].We did indeed find higher levels of these two
chemokines in the C3(1)-Tag tumors compared to the MMTV-Neu
tumors, suggesting that the SV40 large T antigen, through inactivation
of p53, induced an inflammatory response through NF-κB. Thus,
oncogenesis driven by either Ras activation or p53 inactivation likely
elicits transcription of different cytokines by the cancer cells, and these
cytokine differences may drive the difference in the stromal responses.
The different inflammatory environment in the two mouse models
might also contribute to the difference in the effect of MMP9: In the
MMTV-Neu model, the majority of MMP9-expressing cells were
macrophages, while in the C3(1)-Tag model, MMP9 was mostly
supplied by neutrophils. Interestingly, it has previously been shown
that MMP9 supplied by neutrophils better supports tumor
angiogenesis than MMP9 from macrophages [55], likely because
neutrophils secrete MMP9 in a form not bound to its endogenous
inhibitor, tissue inhibitor of metalloproteinase-1 [56,57]. In human
breast cancer, expression of MMP9 protein as detected by
immunohistochemistry has been reported in cancer cells as well as
stromal cells, including macrophages, neutrophils, and pericytes
(reviewed in [21]). An interesting study compared MMP9 protein
(detected by immunohistochemistry) with MMP9 mRNA expres-
sion (detected by in situ hybridization) and found that whereas
macrophages and vascular cells expressed both MMP9 mRNA and
MMP9 protein, breast cancer cells expressed only the protein,
suggesting that it was supplied by the stromal cells [58]. Neutrophils
were similarly found to express MMP9 protein and not MMP9
mRNA, which is consistent with MMP9 protein being already
stored inside the neutrophils for rapid release rather than being
actively synthesized by neutrophils that infiltrate the tumors.
In conclusion, our study highlights the fact that oncogenic alterations
in cancer cells drive specific stromal responses and the function of
proteases depends on the presence of their specific substrates.
Importantly, we show that an extracellularly acting protease, MMP9,
despite being present in bothmodels, only promotes tumor progression
432 Matrix Metalloproteinase 9 in Breast Cancer Park et al. Neoplasia Vol. 17, No. 5, 2015in the C3(1)-Tag model. We provide correlative data suggesting that
IGFBPs, both in murine and human breast tumors, interact with
MMP9 to promote tumorigenesis. However, we had previously found
that the absence of MMP9 results in better responses to the
chemotherapeutic drug doxorubicin in the MMTV-Neu and
MMTV-PyMT models but has no effect in the C3(1)-Tag model
[28]. Together, these findings highlight that MMP9 has multiple
context-dependent functions in the tumor tissue. Our data suggest that
a thorough characterization of the altered expression of oncogenes and
tumor suppressors, as well as the stromal components of human breast
tumors, is needed to inform diagnosis, prognosis, and treatment
regimens of breast cancer patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.04.003.
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